Pentagon

Pentagon Bio is a pre-clinical stage biotechnology company focused on developing precision medicines for the "undruggable" proteome. The company utilizes a proprietary platform to identify and target critical protein-protein interactions (PPIs) that drive cancer and other complex diseases. By combining advanced computational biology with high-throughput screening and structural biology, Pentagon Bio aims to create first-in-class small molecule therapeutics for targets previously considered inaccessible. The company was founded by leading scientists from Stanford University and is backed by a syndicate of prominent venture capital firms. Headquartered in San Carlos, California, Pentagon Bio is advancing a pipeline of oncology programs designed to address significant unmet medical needs in solid tumors.